Multiple Sclerosis News Today | Symptoms, Diagnosis, Treatments
6 天之前 · The National Multiple Sclerosis Society is awarding a total of $4.6 million in funding to advance research into how the protective myelin sheath that’s damaged in multiple sclerosis (MS) can be ...
National MS Society updates Pathways to Cures Roadmap
2024年9月11日 · The original Pathways to Cures Roadmap, published in 2022, was created by the NMSS’s advisory committee and national board of directors, along with the Pathways to Cures task force, which ...
National MS Society awards $4.6M to 5 projects on repairing myelin
3 天之前 · by Margarida Maia, PhD October 16, 2024. The National Multiple Sclerosis Society is awarding a total of $4.6 million in funding to advance research into how the protective myelin sheath that’s ...
Myelin repair boosted in MS mice by genetically modifying...
2 天之前 · by Lindsey Shapiro, PhD October 17, 2024. Transplanting genetically engineered oligodendrocyte progenitor cells (OPCs), which give rise to mature myelin-making cells, significantly boosted myelin ...
Treatment of progressive MS hits milestones in recent years: Study
2024年2月21日 · The study, “ Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges,” was published in The Lancet Neurology. MS has traditionally been ...
Top 10 MS Stories of 2022 - Multiple Sclerosis News Today
2022年12月30日 · This is a list of the top 10 most-read articles we published this past year, with a brief description of each. We look forward to continuing to serve as a resource for the MS community in 2023.
Top 10 Multiple Sclerosis Stories of 2021
2022年1月3日 · No. 1 — “ Never Drinking Alcohol Tied to ‘Significantly’ Higher MS Risk”. Our most-read story of 2021 concerned results demonstrating that people who never drank alcohol were ...
Clinical trial of oditrasertib in MS patients stopped, goals not met
4 天之前 · by Lindsey Shapiro, PhD October 15, 2024. Sanofi has ended a Phase 2 clinical trial into oditrasertib, an investigational RIPK1 inhibitor therapy, in people with relapsing and progressive multiple ...
Early High-efficacy DMTs Better at Eliminating MS Activity, Study...
2021年7月7日 · The study, “ Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry,” was published in ...
Myelin repair early in MS may protect against disability worsening
2024年1月31日 · None of the myelin measurements showed clear associations with patients’ age or MS type. Individuals who’d been living with MS for longer have significantly more extensive demyelination at ...